In 2013, new insights on the molecular features of cutaneous melanoma provided a paradigm shift in our understanding of the biology of this disease. Exploiting immune checkpoint blockade and the use of BRAF-targeted or MAPK-targeted agents contributed to important progress in the treatment and management of cutaneous melanoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Nature Communications Open Access 03 May 2023
-
Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway
Cancer Cell International Open Access 29 November 2021
-
Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression
Acta Neuropathologica Communications Open Access 16 November 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eggermont, A. M., Spatz, A. & Robert, C. Cutaneous melanoma. Lancet http://dx.doi.org/10.1016/S0140-6736(13)60802-8.
Trunzer, K. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767–1774 (2013).
Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013).
Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B (high) cells. Cancer Cell 23, 811–825 (2013).
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
Knight, D. A. et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371–1381 (2013).
Ribas, A. et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365–1366 (2013).
Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961 (2013).
Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Schadendorf and A. Hauschild are consultants and advisory board members of Amgen, Bristol–Myers Squibb, Genentech, GlaxoSmithKline, Merck/MSD, Novartis, Pfizer and Roche. D. Schadendorf and A. Hauschild receive trial grants from these companies.
Rights and permissions
About this article
Cite this article
Schadendorf, D., Hauschild, A. Melanoma—the run of success continues. Nat Rev Clin Oncol 11, 75–76 (2014). https://doi.org/10.1038/nrclinonc.2013.246
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.246
This article is cited by
-
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Nature Communications (2023)
-
Protein expression of prognostic genes in primary melanoma and benign nevi
Journal of Cancer Research and Clinical Oncology (2022)
-
Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway
Cancer Cell International (2021)
-
Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression
Acta Neuropathologica Communications (2021)
-
Bacterial type III effector protein HopQ inhibits melanoma motility through autophagic degradation of vimentin
Cell Death & Disease (2020)
